Ardent Health, Inc.
ARDTAnalytical Summary
Ardent Health, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
4-Year Financial Trajectory
AnnualHealth Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
6.0%
Fair
↓
Fair
Declining
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-25%)
|
10.3%
Good
Good
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+29%)
|
5.5%
Fair
Fair
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-32%)
|
— |
| EPS Growth YoY (%) |
-39.6%
Weak
↓
Weak
Declining
Year-over-year change in earnings per share
Optimal:
> 10%
|
269.8%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
-71.3%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— |
| Net Income Growth YoY (%) |
-35.4%
Weak
↓
Weak
Declining
Year-over-year change in net income |
290.2%
Excellent
Excellent
Year-over-year change in net income |
-71.5%
Weak
Weak
Year-over-year change in net income |
— |
| FCF Growth YoY (%) |
40.5%
Excellent
Excellent
Year-over-year change in free cash flow |
35.3%
Excellent
Excellent
Year-over-year change in free cash flow |
N/M | — |
| Revenue CAGR 3Y (%) |
7.2%
Fair
Fair
Compound annual revenue growth over 3 years |
— | — | — |
| EPS CAGR 3Y (%) |
-13.8%
Weak
Weak
Compound annual EPS growth over 3 years |
— | — | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
19.6%
Good
↑
Good
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
17.4%
Good
↑
Good
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
14.9%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
14.8%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
| Profit Margin (%) (%) |
2.1%
Weak
↓
Weak
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-82%)
|
3.5%
Weak
↑
Weak
Improving
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-71%)
|
1.0%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-92%)
|
3.7%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-69%)
|
| FCF Margin (%) (%) |
7.4%
Caution
↑
Caution
Improving
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
5.3%
Caution
↑
Caution
Improving
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
4.1%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-0.7%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
| FCF / Net Income (x) |
3.46x
Excellent
↑
Excellent
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.50x
Good
↓
Good
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
4.11x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.20x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Common Equity (%) (%) |
10.5%
Fair
↓
Fair
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-30%)
|
18.6%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+24%)
|
8.0%
Caution
Caution
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-46%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) |
0.87x
Fair
↓
Fair
Declining
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+44%)
|
0.98x
Fair
Fair
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+64%)
|
1.74x
Weak
Weak
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+190%)
|
— |
| Net Debt (USD) | $406.36M | $557.29M | $730.68M | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $6.32B | $5.97B | $5.41B | $5.13B |
| Depreciation Expense (USD) | $155.70M | $146.29M | $140.84M | $138.17M |
| Net Income, GAAP (USD) | $135.81M | $210.34M | $53.90M | $188.91M |
| Operating Cash Flow (USD) | $470.51M | $315.03M | $221.70M | $-38.36M |
Secondary lens
Benchmark Lens
Compare ARDT against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ARDT against peers after checking the statement evidence.
Percentile Rankings
How ARDT compares to all companies
Peer Comparison
ARDT vs similar peers
Compare ARDT with peers
Stack ARDT against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 13 quarters